Upwards arrow: Go back to top

Join us on LinkedIn for the latest news.

News & Press

Learn more about recent advances in biotech, health tech and our work.

Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic MalignanciesAuron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
29.5.2025
Auron Announces First Patient Dosed in Phase 1 Clinical Trial of AUTX-703 in Advanced Hematologic Malignancies
Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease PipelineTherini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
14.5.2025
Therini Bio Raises Additional $39M Series A Financing to Advance Clinical Development of Neurodegenerative Disease Pipeline
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related DiseasesHAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
8.5.2025
HAYA Therapeutics Raises $65 Million in Series A Funding to Deliver Precision RNA-Guided Medicines for Chronic and Age-Related Diseases
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous LeukemiaAuron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
24.2.2025
Auron Therapeutics Announces AUTX-703 Granted Fast Track Designation by the FDA for Relapsed or Refractory Acute Myelogenous Leukemia
Auron Therapeutics secures FDA clearance & $27M Series B to advance precision oncologyAuron Therapeutics secures FDA clearance & $27M Series B to advance precision oncology
4.2.2025
Auron Therapeutics secures FDA clearance & $27M Series B to advance precision oncology
Booster Therapeutics launches with $15 M seed financingBooster Therapeutics launches with $15 M seed financing
10.10.2024
Booster Therapeutics launches with $15 M seed financing led by Apollo Health Ventures and Novo Holdings
HAYA Therapeutics Announces collaboartion with LillyHAYA Therapeutics Announces collaboartion with Lilly
4.9.2024
HAYA Therapeutics enters partnership with Eli Lilly worth up to $1 B to discover new genome targets for obesity and related metabolic conditions
GSK enters into a multi-year data licence agreement with Ochre BioGSK enters into a multi-year data licence agreement with Ochre Bio
17.7.2024
GSK enters into a multi-year data licence agreement with Ochre Bio